{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:53:43Z","timestamp":1769604823511,"version":"3.49.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40263-024-01107-x","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T04:01:39Z","timestamp":1721620899000},"page":"661-670","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Psychotropic Drugs Reemerging as Headache Medicines"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7962-0365","authenticated-orcid":false,"given":"Emmanuelle A. D.","family":"Schindler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"issue":"1","key":"1107_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia Int J Headache. 2018;38(1):1\u2013211.","journal-title":"Cephalalgia Int J Headache."},{"issue":"2","key":"1107_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11910-010-0175-6","volume":"11","author":"ME Bigal","year":"2011","unstructured":"Bigal ME, Lipton RB. Migraine chronification. Curr Neurol Neurosci Rep. 2011;11(2):139\u201348.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"1","key":"1107_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2165\/00003495-200262010-00003","volume":"62","author":"K Ekbom","year":"2002","unstructured":"Ekbom K, Hardebo JE. Cluster headache: aetiology, diagnosis and management. Drugs. 2002;62(1):61\u20139.","journal-title":"Drugs"},{"issue":"3","key":"1107_CR4","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.cden.2013.04.005","volume":"57","author":"R Benoliel","year":"2013","unstructured":"Benoliel R, Eliav E. Primary headache disorders. Dent Clin North Am. 2013;57(3):513\u201339.","journal-title":"Dent Clin North Am"},{"issue":"7","key":"1107_CR5","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1111\/head.12866","volume":"56","author":"MS Robbins","year":"2016","unstructured":"Robbins MS, Starling AJ, Pringsheim TM, Becker WJ, Schwedt TJ. Treatment of cluster headache: The American Headache Society evidence-based guidelines. Headache. 2016;56(7):1093\u2013106.","journal-title":"Headache"},{"key":"1107_CR6","volume-title":"Cluster Headache Preventive Therapies","author":"EAD Schindler","year":"2019","unstructured":"Schindler EAD, Gottschalk CH. Cluster Headache Preventive Therapies. Wayne: Bryn Mawr Communications; 2019."},{"issue":"2","key":"1107_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.mcna.2018.10.003","volume":"103","author":"R Burch","year":"2019","unstructured":"Burch R. Migraine and tension-type headache: diagnosis and treatment. Med Clin North Am. 2019;103(2):215\u201333.","journal-title":"Med Clin North Am"},{"issue":"8","key":"1107_CR8","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/j.1526-4610.1991.hed3108525.x","volume":"31","author":"PJ Mather","year":"1991","unstructured":"Mather PJ, Silberstein SD, Schulman EA, Hopkins MM. The treatment of cluster headache with repetitive intravenous dihydroergotamine. Headache. 1991;31(8):525\u201332.","journal-title":"Headache"},{"issue":"3","key":"1107_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1526-4610.2004.04055.x","volume":"44","author":"E Magnoux","year":"2004","unstructured":"Magnoux E, Zlotnik G. Outpatient intravenous dihydroergotamine for refractory cluster headache. Headache. 2004;44(3):249\u201355.","journal-title":"Headache"},{"issue":"20","key":"1107_CR10","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1212\/WNL.0b013e3182377dbb","volume":"77","author":"AJ Nagy","year":"2011","unstructured":"Nagy AJ, Gandhi S, Bhola R, Goadsby PJ. Intravenous dihydroergotamine for inpatient management of refractory primary headaches. Neurology. 2011;77(20):1827\u201332.","journal-title":"Neurology"},{"issue":"7","key":"1107_CR11","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.cell.2018.11.049","volume":"175","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L. CGRP antibodies as prophylaxis in migraine. Cell. 2018;175(7):1719.","journal-title":"Cell"},{"issue":"2","key":"1107_CR12","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa1813440","volume":"381","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Dodick DW, Leone M, Bardos JN, Oakes TM, Millen BA, et al. Trial of galcanezumab in prevention of episodic cluster headache. N Engl J Med. 2019;381(2):132\u201341.","journal-title":"N Engl J Med"},{"issue":"3","key":"1107_CR13","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/j.1749-6632.1957.tb40738.x","volume":"66","author":"H Osmond","year":"1957","unstructured":"Osmond H. A review of the clinical effects of psychotomimetic agents. Ann N Y Acad Sci. 1957;66(3):418\u201334.","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"1107_CR14","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE. Psychedelics. Pharmacol Rev. 2016;68(2):264\u2013355.","journal-title":"Pharmacol Rev"},{"issue":"3","key":"1107_CR15","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/head.12025","volume":"53","author":"BE McGeeney","year":"2013","unstructured":"McGeeney BE. Cannabinoids and hallucinogens for headache. Headache. 2013;53(3):447\u201358.","journal-title":"Headache"},{"issue":"12","key":"1107_CR16","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1212\/01.wnl.0000219761.05466.43","volume":"66","author":"RA Sewell","year":"2006","unstructured":"Sewell RA, Halpern JH, Pope HG Jr. Response of cluster headache to psilocybin and LSD. Neurology. 2006;66(12):1920\u20132.","journal-title":"Neurology"},{"issue":"2","key":"1107_CR17","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/j.1526-4610.2010.01808_1.x","volume":"51","author":"RA Sewell","year":"2011","unstructured":"Sewell RA, Gottschalk CH. Problem child is no headache. Headache. 2011;51(2):306 (author reply -7).","journal-title":"Headache"},{"issue":"5","key":"1107_CR18","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1080\/02791072.2015.1107664","volume":"47","author":"EA Schindler","year":"2015","unstructured":"Schindler EA, Gottschalk CH, Weil MJ, Shapiro RE, Wright DA, Sewell RA. Indoleamine hallucinogens in cluster headache: results of the Clusterbusters Medication Use survey. J Psychoactive Drugs. 2015;47(5):372\u201381.","journal-title":"J Psychoactive Drugs"},{"issue":"1","key":"1107_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/head.14021","volume":"61","author":"MJ Burish","year":"2021","unstructured":"Burish MJ, Pearson SM, Shapiro RE, Zhang W, Schor LI. Cluster headache is one of the most intensely painful human conditions: Results from the International Cluster Headache Questionnaire. Headache. 2021;61(1):117\u201324.","journal-title":"Headache"},{"issue":"2","key":"1107_CR20","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/head.14063","volume":"61","author":"EAD Schindler","year":"2021","unstructured":"Schindler EAD, Cooper V, Quine DB, Fenton BT, Wright DA, Weil MJ, et al. \u201cYou will eat shoe polish if you think it would help\u201d-Familiar and lesser-known themes identified from mixed-methods analysis of a cluster headache survey. Headache. 2021;61(2):318\u201328.","journal-title":"Headache"},{"key":"1107_CR21","volume-title":"Psychedelic outlaws : the movement revolutionizing modern medicine","author":"J Kempner","year":"2024","unstructured":"Kempner J. Psychedelic outlaws\u202f: the movement revolutionizing modern medicine. 1st ed. New York: Hachette Books; 2024.","edition":"1"},{"issue":"10","key":"1107_CR22","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1111\/head.14420","volume":"62","author":"EAD Schindler","year":"2022","unstructured":"Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Zhu Y, et al. Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double-blind, placebo-controlled trial. Headache. 2022;62(10):1383\u201394.","journal-title":"Headache"},{"key":"1107_CR23","doi-asserted-by":"crossref","unstructured":"Schindler EAD, Sewell RA, Gottschalk CH, Flynn LT, Zhou Y, Pittman BP, et al. Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial. J Neurol Sci. 2024;460:122993.","DOI":"10.1016\/j.jns.2024.122993"},{"issue":"1","key":"1107_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/head.14656","volume":"64","author":"MK Madsen","year":"2024","unstructured":"Madsen MK, Petersen AS, Stenbaek DS, Sorensen IM, Schionning H, Fjeld T, et al. CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity. Headache. 2024;64(1):55\u201367.","journal-title":"Headache"},{"issue":"11","key":"1107_CR25","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1111\/j.1468-2982.2008.01648.x","volume":"28","author":"PJ Koehler","year":"2008","unstructured":"Koehler PJ, Tfelt-Hansen PC. History of methysergide in migraine. Cephalalgia Int J Headache. 2008;28(11):1126\u201335.","journal-title":"Cephalalgia Int J Headache."},{"key":"1107_CR26","first-page":"116","volume":"6","author":"F Sicuteri","year":"1963","unstructured":"Sicuteri F. Prophylactic treatment of migraine by means of lysergic acid derivatives. Triangle Sandoz J Med Sci. 1963;6:116\u201325.","journal-title":"Triangle Sandoz J Med Sci"},{"issue":"1","key":"1107_CR27","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12954-017-0186-6","volume":"14","author":"M Andersson","year":"2017","unstructured":"Andersson M, Persson M, Kjellgren A. Psychoactive substances as a last resort-a qualitative study of self-treatment of migraine and cluster headaches. Harm Reduct J. 2017;14(1):60.","journal-title":"Harm Reduct J"},{"key":"1107_CR28","unstructured":"Migrainebusters. Psilocybin and Migraine Disease. 2023 [cited; Available from: https:\/\/survey.zohopublic.com\/zs\/pqz7BQ. Accessed 8 Apr 2024"},{"issue":"1","key":"1107_CR29","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s13311-020-00962-y","volume":"18","author":"EAD Schindler","year":"2021","unstructured":"Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Lindsey H, et al. Exploratory controlled study of the migraine-suppressing effects of psilocybin. Neurotherapeutics. 2021;18(1):534\u201343.","journal-title":"Neurotherapeutics"},{"issue":"9","key":"1107_CR30","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11916-023-01145-y","volume":"27","author":"EAD Schindler","year":"2023","unstructured":"Schindler EAD. The potential of psychedelics for the treatment of episodic migraine. Curr Pain Headache Rep. 2023;27(9):489\u201395.","journal-title":"Curr Pain Headache Rep"},{"issue":"9","key":"1107_CR31","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1177\/0333102410363490","volume":"30","author":"M Karst","year":"2010","unstructured":"Karst M, Halpern JH, Bernateck M, Passie T. The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: an open, non-randomized case series. Cephalalgia Int J Headache. 2010;30(9):1140\u20134.","journal-title":"Cephalalgia Int J Headache."},{"issue":"5","key":"1107_CR32","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1021\/cr078224o","volume":"108","author":"DE Nichols","year":"2008","unstructured":"Nichols DE, Nichols CD. Serotonin receptors. Chem Rev. 2008;108(5):1614\u201341.","journal-title":"Chem Rev"},{"issue":"10","key":"1107_CR33","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1080\/14737175.2023.2246655","volume":"23","author":"EAD Schindler","year":"2023","unstructured":"Schindler EAD, Hendricks PS. Adapting psychedelic medicine for headache and chronic pain disorders. Expert Rev Neurother. 2023;23(10):867\u201382.","journal-title":"Expert Rev Neurother"},{"issue":"215","key":"1107_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109166","volume":"1","author":"EAD Schindler","year":"2022","unstructured":"Schindler EAD. Psychedelics as preventive treatment in headache and chronic pain disorders. Neuropharmacology. 2022;1(215): 109166.","journal-title":"Neuropharmacology"},{"issue":"17","key":"1107_CR35","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.1111\/bph.13222","volume":"172","author":"D Lodge","year":"2015","unstructured":"Lodge D, Mercier MS. Ketamine and phencyclidine: the good, the bad and the unexpected. Br J Pharmacol. 2015;172(17):4254\u201376.","journal-title":"Br J Pharmacol"},{"issue":"5","key":"1107_CR36","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","volume":"178","author":"RS McIntyre","year":"2021","unstructured":"McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry. 2021;178(5):383\u201399.","journal-title":"Am J Psychiatry"},{"issue":"5","key":"1107_CR37","first-page":"521","volume":"43","author":"SP Cohen","year":"2018","unstructured":"Cohen SP, Bhatia A, Buvanendran A, Schwenk ES, Wasan AD, Hurley RW, et al. Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018;43(5):521\u201346.","journal-title":"Reg Anesth Pain Med"},{"issue":"9","key":"1107_CR38","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrn2884","volume":"11","author":"FX Vollenweider","year":"2010","unstructured":"Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci. 2010;11(9):642\u201351.","journal-title":"Nat Rev Neurosci"},{"issue":"7","key":"1107_CR39","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s00210-023-02444-2","volume":"396","author":"K Podkowa","year":"2023","unstructured":"Podkowa K, Czarnacki K, Boronczyk A, Boronczyk M, Paprocka J. The NMDA receptor antagonists memantine and ketamine as anti-migraine agents. Naunyn Schmiedebergs Arch Pharmacol. 2023;396(7):1371\u201398.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"6","key":"1107_CR40","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/j.1526-4610.2012.02185.x","volume":"52","author":"E Loder","year":"2012","unstructured":"Loder E, Burch R, Rizzoli P. The 2012 AHS\/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache. 2012;52(6):930\u201345.","journal-title":"Headache"},{"key":"1107_CR41","doi-asserted-by":"crossref","unstructured":"Domitrz I, Cegielska J. Magnesium as an important factor in the pathogenesis and treatment of migraine-from theory to practice. Nutrients. 2022;14(5):1089.","DOI":"10.3390\/nu14051089"},{"issue":"12","key":"1107_CR42","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1136\/rapm-2022-104223","volume":"48","author":"H Yuan","year":"2023","unstructured":"Yuan H, Natekar A, Park J, Lauritsen CG, Viscusi ER, Marmura MJ. Real-world study of intranasal ketamine for use in patients with refractory chronic migraine: a retrospective analysis. Reg Anesth Pain Med. 2023;48(12):581\u20137.","journal-title":"Reg Anesth Pain Med"},{"issue":"1","key":"1107_CR43","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/head.14220","volume":"62","author":"AS Petersen","year":"2022","unstructured":"Petersen AS, Pedersen AS, Barloese MCJ, Holm P, Pedersen O, Jensen RH, et al. Intranasal ketamine for acute cluster headache attacks-Results from a proof-of-concept open-label trial. Headache. 2022;62(1):26\u201335.","journal-title":"Headache"},{"key":"1107_CR44","unstructured":"Das S. Ketamine clinics are jumping ahead of the evidence\u2014New mental health treatments must be approached with caution. Medpage Today; 2023. p. https:\/\/www.medpagetoday.com\/opinion\/second-opinions\/102956. Accessed 8 Apr 2024"},{"key":"1107_CR45","unstructured":"Manlove S. How to steer clear of the ketamine wild west. Advanced Brain and Body Clinic; 2023. p. https:\/\/www.advancedbrainbody.com\/blog\/how-to-steer-clear-of-the-ketamine-wild-west\/. Accessed 8 Apr 2024"},{"issue":"6","key":"1107_CR46","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1177\/0897190014525754","volume":"27","author":"G Bokor","year":"2014","unstructured":"Bokor G, Anderson PD. Ketamine: an update on its abuse. J Pharm Pract. 2014;27(6):582\u20136.","journal-title":"J Pharm Pract"},{"issue":"11","key":"1107_CR47","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/S2215-0366(22)00317-0","volume":"9","author":"SY Smith-Apeldoorn","year":"2022","unstructured":"Smith-Apeldoorn SY, Veraart JK, Spijker J, Kamphuis J, Schoevers RA. Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability. Lancet Psychiatry. 2022;9(11):907\u201321.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"1107_CR48","first-page":"1","volume":"38","author":"LE Hollister","year":"1986","unstructured":"Hollister LE. Health aspects of cannabis. Pharmacol Rev. 1986;38(1):1\u201320.","journal-title":"Pharmacol Rev"},{"issue":"7","key":"1107_CR49","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/head.13345","volume":"58","author":"EP Baron","year":"2018","unstructured":"Baron EP. Medicinal properties of cannabinoids, terpenes, and flavonoids in cannabis, and benefits in migraine, headache, and pain: an update on current evidence and cannabis science. Headache. 2018;58(7):1139\u201386.","journal-title":"Headache"},{"issue":"1","key":"1107_CR50","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s10194-023-01589-y","volume":"24","author":"R Greco","year":"2023","unstructured":"Greco R, Francavilla M, Demartini C, Zanaboni AM, Sodergren MH, Facchetti S, et al. Characterization of the biochemical and behavioral effects of cannabidiol: implications for migraine. J Headache Pain. 2023;24(1):48.","journal-title":"J Headache Pain"},{"issue":"124","key":"1107_CR51","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.neuropharm.2017.06.015","volume":"15","author":"SG Woodhams","year":"2017","unstructured":"Woodhams SG, Chapman V, Finn DP, Hohmann AG, Neugebauer V. The cannabinoid system and pain. Neuropharmacology. 2017;15(124):105\u201320.","journal-title":"Neuropharmacology"},{"issue":"1","key":"1107_CR52","first-page":"94","volume":"51","author":"I Urits","year":"2021","unstructured":"Urits I, Charipova K, Gress K, Li N, Berger AA, Cornett EM, et al. Adverse effects of recreational and medical cannabis. Psychopharmacol Bull. 2021;51(1):94\u2013109.","journal-title":"Psychopharmacol Bull"},{"issue":"6","key":"1107_CR53","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1038\/sj.npp.1301246","volume":"32","author":"P Sarchielli","year":"2007","unstructured":"Sarchielli P, Pini LA, Coppola F, Rossi C, Baldi A, Mancini ML, et al. Endocannabinoids in chronic migraine: CSF findings suggest a system failure. Neuropsychopharmacology. 2007;32(6):1384\u201390.","journal-title":"Neuropsychopharmacology"},{"key":"1107_CR54","doi-asserted-by":"crossref","unstructured":"Heiliczer S, Wilensky A, Gaver T, Georgiev O, Hamad S, Nemirovski A, et al. Salivary endocannabinoid profiles in chronic orofacial pain and headache disorders: an observational study using a novel tool for diagnosis and management. Int J Mol Sci. 2022;23(21):13017.","DOI":"10.3390\/ijms232113017"},{"issue":"3","key":"1107_CR55","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1177\/0333102412468669","volume":"33","author":"E Leroux","year":"2013","unstructured":"Leroux E, Taifas I, Valade D, Donnet A, Chagnon M, Ducros A. Use of cannabis among 139 cluster headache sufferers. Cephalalgia Int J Headache. 2013;33(3):208\u201313.","journal-title":"Cephalalgia Int J Headache."},{"issue":"5","key":"1107_CR56","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1177\/0333102418804160","volume":"39","author":"IF de Coo","year":"2019","unstructured":"de Coo IF, Naber WC, Wilbrink LA, Haan J, Ferrari MD, Fronczek R. Increased use of illicit drugs in a Dutch cluster headache population. Cephalalgia Int J Headache. 2019;39(5):626\u201334.","journal-title":"Cephalalgia Int J Headache."},{"key":"1107_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.871187","volume":"13","author":"BO Okusanya","year":"2022","unstructured":"Okusanya BO, Lott BE, Ehiri J, McClelland J, Rosales C. Medical cannabis for the treatment of migraine in adults: a review of the evidence. Front Neurol. 2022;13: 871187.","journal-title":"Front Neurol"},{"issue":"1","key":"1107_CR58","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/14737175.2023.2174017","volume":"23","author":"M Nicholas","year":"2023","unstructured":"Nicholas M, Erridge S, Bapir L, Pillai M, Dalavaye N, Holvey C, et al. UK medical cannabis registry: assessment of clinical outcomes in patients with headache disorders. Expert Rev Neurother. 2023;23(1):85\u201396.","journal-title":"Expert Rev Neurother"},{"issue":"8","key":"1107_CR59","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10194-012-0490-1","volume":"13","author":"LA Pini","year":"2012","unstructured":"Pini LA, Guerzoni S, Cainazzo MM, Ferrari A, Sarchielli P, Tiraferri I, et al. Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial. J Headache Pain. 2012;13(8):677\u201384.","journal-title":"J Headache Pain"},{"key":"1107_CR60","doi-asserted-by":"crossref","unstructured":"Schuster NM, Wallace MS, Marcotte TD, Buse DC, Lee E, Liu L, et al. Vaporized cannabis versus placebo for acute migraine: a randomized controlled trial. medRxiv. 2024.","DOI":"10.1101\/2024.02.16.24302843"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01107-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-024-01107-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01107-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T07:24:39Z","timestamp":1723447479000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-024-01107-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1107"],"URL":"https:\/\/doi.org\/10.1007\/s40263-024-01107-x","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]},"assertion":[{"value":"2 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"E.A.D.S. currently receives research funding from the National Headache Foundation and the Wallace Research Foundation and previously received research funding from Ceruvia Lifesciences, Heffter Research Institute, and Clusterbusters. She serves on the scientific advisory boards for Ceruvia Lifesciences, Clusterbusters, and OptoSom and previously served as a consultant for PureTech Health. She is listed as an inventor on patent US20210236523A1.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material:"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability:"}},{"value":"E.A.D.S. was the sole contributor to the article and agrees to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}